Clinical trials: Meibomian Gland Dysfunction (Disorder)
Dry Eye Syndromes
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
The purpose of this study is to evaluate if, in patients with meibomian gland dysfunction (MGD), treatment with the Lumenis M22 Intense Pulsed Light (IPL) system causes a reduction in dry eye symptoms post-treatment, compared to…
- Trial name
- NCT02621593
- Testing
- M22-IPL
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Lumenis Be Ltd.
Dry Eye Syndrome
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction.
- Trial name
- NCT03396913
- Testing
- IPL, MGX
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Lumenis Be Ltd.
Meibomian Gland Dysfunction
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical…
- Trial name
- NCT05261386
- Testing
- CBT-008
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Cloudbreak Therapeutics, LLC
Meibomian Gland Dysfunction, Evaporative Dry Eye Disease
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.
- Trial name
- NCT03956225
- Testing
- Systane iLux® Dry Eye System, LipiFlow® Thermal Pulsation System
- Where
- 15 sites in United States
- Volunteers
- 299 people
- Sponsor
- Alcon Research
Evaporative Dry Eye Disease
Comparative Efficacy Study to Demonstrate the Non-inferiority of I-DROP® MGD Versus 2 Competitor Eye Drops in Managing Evaporative Dry Eye
A Pilot Comparative study between I-DROP MGD vs two commercially available lubricant eye drops for the management of evaporative dry eye
- Trial name
- NCT06686368
- Testing
- I-DROP MGD, Theloze Duo, Systane Complete PF
- Volunteers
- 60 people
- Sponsor
- I-MED Pharma
Meibomian Gland Dysfunction, Dry Eye
A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
- Trial name
- NCT03652051
- Testing
- AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose, AZR-MD-001 High Dose
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 321 people
- Sponsor
- Azura Ophthalmics
Chalazion, Dry Eye Syndromes
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
The objective is to evaluate the feasibility of using additional screening methods to optimize effectiveness outcomes with the LipiFlow System for application of heat and pressure therapy in adult patients with chronic cystic…
- Trial name
- NCT01202747
- Testing
- LipiFlow System
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- TearScience, Inc.
Dry Eye, Meibomian Gland Dysfunction
Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
- Trial name
- NCT04795752
- Testing
- TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
- Where
- 14 sites in United States
- Volunteers
- 345 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye Disease
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with…
- Trial name
- NCT04567329
- Testing
- NOV03, Saline Solution
- Where
- 35 sites in United States
- Volunteers
- 620 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease (DED)
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland…
- Trial name
- NCT04139798
- Testing
- NOV03
- Where
- 29 sites in United States
- Volunteers
- 599 people
- Sponsor
- Bausch & Lomb Incorporated
Meibomian Gland Dysfunction, Dry Eye
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
The pilot study objective is to evaluate the potential benefits of LipiFlow® System treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye by assessing for improvement in meibomian gland…
- Trial name
- NCT02102464
- Testing
- LipiFlow treatment
- Where
- 6 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- TearScience, Inc.
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction
The study is being conducted to evaluate the efficacy and safety of SHR8058 eye drops for patients with dry eye disease.
- Trial name
- NCT05515471
- Testing
- SHR8058 eye drops, saline eye drops.
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Meibomian Gland Dysfunction
A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.
- Trial name
- NCT01633788
- Testing
- AGN-195263 0.1%, AGN-195263 0.03%, AGN-195263 0.01%
- Where
- 33 sites in United States
- Volunteers
- 232 people
- Sponsor
- Allergan
Meibomian Gland Dysfunction, Dry Eye Disease
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
- Trial name
- NCT06064071
- Testing
- Nordlys SWT IPL, Meibomian Gland Expression (MGX)
- Where
- 3 sites in United States, Argentina
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Blepharitis
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.
- Trial name
- NCT00656539
- Testing
- AzaSite®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Meibomian Gland Dysfunction, Dry Eye Syndromes
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
- Trial name
- NCT05162261
- Testing
- Tixel C, LipiFlow
- Where
- 5 sites in United States
- Volunteers
- 109 people
- Sponsor
- Novoxel Ltd.
Dry Eye, Meibomian Gland Dysfunction
Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction
The purpose of this study is assess the efficacy and safety of topical hydrocortisone (Softacort) for treatment of clinical signs and symptoms of dry eye disease when associated with moderate meibomian gland dysfunction.
- Trial name
- NCT05159284
- Testing
- Hydrocortisone Ophthalmic, MGD Rx EyeBag® eyelid warming device, Lephanet® lid wipes
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Laboratorios Thea, Spain
Dry Eye, Meibomian Gland Dysfunction
Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction
This study is a multicentric, comparative, randomized, investigator-blinded, in parallel groups study to demonstrate the non-inferiority of Neovis® Total Multi in comparison with Systane® Balance, in terms of improvement of…
- Trial name
- NCT05191771
- Testing
- Neovis Total Multi, Systane Balance
- Volunteers
- 120 people
- Sponsor
- Horus Pharma
Meibomian Gland Dysfunction, Blepharitis
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
- Trial name
- Ersa (NCT05454956)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Bilateral Blepharitis (Disorder)
To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis
The purpose of this study is to evaluate the efficacy of, and patient satisfaction with Blephapad Combo in the treatment of posterior blepharitis.
- Trial name
- NCT03301844
- Testing
- Blephapad Combo, Standard treatment
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- NTC srl